Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Relationship Between EGFR Expression, EGFR

Relationship Between EGFR Expression, EGFR Original Atricle Mutation Status, and the Efficacy of Chemotherapy Plus   Cetuximab in FLEX Study Patients with Advanced  Non–Small-Cell Lung Cancer Jean-Yves Douillard, MD, PhD,* Robert Pirker, MD,† Kenneth J. O’Byrne, MD,‡ Keith M. Kerr, FRCPath,§ Stephan Störkel, MD,‖ Anja von Heydebreck, PhD,¶ Hans Jürgen Grote, MD,# Ilhan Celik, MD,** and Frances A. Shepherd, MD†† expression level. The most common mutations were exon 19 dele- Introduction: The phase III FLEX study (NCT00148798) in tions and L858R (124 of 133 patients; 93%). In the high EGFR advanced non–small-cell lung cancer indicated that the survival expression group (immunohistochemistry score of ≥200), a survival benefit associated with the addition of cetuximab to cisplatin and benefit for the addition of cetuximab to chemotherapy was demon- vinorelbine was limited to patients whose tumors expressed high lev- strated in patients with EGFR wild-type (including T790M mutant) els of epidermal growth factor receptor (EGFR) (immunohistochem- tumors. Although patient numbers were small, those in the high istry score of ≥200; scale 0–300). We assessed whether the treatment EGFR expression group whose tumors carried EGFR mutations may effect was also modulated in FLEX study patients by tumor EGFR also have derived a survival benefit from the addition of cetuximab mutation status. to chemotherapy. Response data suggested a cetuximab benefit in the Methods: A http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Relationship Between EGFR Expression, EGFR

Shepherd, Frances A.
Journal of Thoracic Oncology , Volume 9 (5) – May 1, 2014
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/relationship-between-egfr-expression-egfr-P9WWZ40JZX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

Original Atricle Mutation Status, and the Efficacy of Chemotherapy Plus   Cetuximab in FLEX Study Patients with Advanced  Non–Small-Cell Lung Cancer Jean-Yves Douillard, MD, PhD,* Robert Pirker, MD,† Kenneth J. O’Byrne, MD,‡ Keith M. Kerr, FRCPath,§ Stephan Störkel, MD,‖ Anja von Heydebreck, PhD,¶ Hans Jürgen Grote, MD,# Ilhan Celik, MD,** and Frances A. Shepherd, MD†† expression level. The most common mutations were exon 19 dele- Introduction: The phase III FLEX study (NCT00148798) in tions and L858R (124 of 133 patients; 93%). In the high EGFR advanced non–small-cell lung cancer indicated that the survival expression group (immunohistochemistry score of ≥200), a survival benefit associated with the addition of cetuximab to cisplatin and benefit for the addition of cetuximab to chemotherapy was demon- vinorelbine was limited to patients whose tumors expressed high lev- strated in patients with EGFR wild-type (including T790M mutant) els of epidermal growth factor receptor (EGFR) (immunohistochem- tumors. Although patient numbers were small, those in the high istry score of ≥200; scale 0–300). We assessed whether the treatment EGFR expression group whose tumors carried EGFR mutations may effect was also modulated in FLEX study patients by tumor EGFR also have derived a survival benefit from the addition of cetuximab mutation status. to chemotherapy. Response data suggested a cetuximab benefit in the Methods: A

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2014

There are no references for this article.